Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | RAD52 | P43351 | 1/20 | 0.73 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616998 | 0.86 | KDM4E (0.97) | KDM4ERAD52KMT2ATDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6605580 | 0.85 | KDM4E (1.00) | KDM4ERAD52KMT2ATDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16736724 | 0.85 | KDM4E (1.00) | KDM4ERAD52KMT2ATDP1ALDH1A1 | |
| SCHEMBL939056 | 0.84 | TLR8 (0.56) | KDM4ERAD52ACSS2KMT2AALDH1A1 | |
| SCHEMBL21803210 | 0.82 | ACSS2 (0.55) | KDM4ERAD52ACSS2KMT2ATDP1 | |
| SCHEMBL617957 | 0.82 | KDM4E (0.51) | KDM4ERAD52ACSS2ALDH1A1HPGD | |
| SCHEMBL623380 | 0.81 | KDM4E (0.51) | KDM4ERAD52ACSS2KMT2ATDP1 | |
| SCHEMBL615476 | 0.80 | TNF (0.68) | KDM4ERAD52ACSS2ALDH1A1HPGD | |
| SCHEMBL3622413 | 0.80 | KDM4E (0.49) | KDM4ERAD52ACSS2KMT2ATDP1 | |
| SCHEMBL21803208 | 0.79 | KDM4E (0.51) | KDM4ERAD52ACSS2KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | KDM4E 2033/4885RAD52 2526/4885ACSS2 405/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | KDM4E 565/4885RAD52 947/4885ACSS2 3183/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | KDM4E 565/4885RAD52 947/4885ACSS2 3183/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | KDM4E 893/4885RAD52 762/4885ACSS2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.